Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic hepatitis C, genotype 1 infection with interleukin 28B (IL28B) rs12979860 genotype C/C.~* Liver biopsy within 3 years with histology consistent with hepatitis C virus (HCV) - induced liver damage, with no evidence of cirrhosis or liver pathology due to any cause other than chronic HCV.~* Treatment naïve male or female between the ages of 18 and 65.~* Females must be postmenopausal for at least 2 years or surgically sterile.~* Be in a condition of general good health, as perceived by the investigator, other than hepatitis C virus infection.~* Body mass index 18 to \< 35 kg/m\^2 .~Exclusion Criteria:~* Significant sensitivity to any drug.~* Use of herbal supplements within 2 weeks prior to study drug dosing.~* Positive screen for certain drugs or alcohol.~* Positive hepatitis B surface antigen or anti-human immunodeficiency virus (HIV) antibody.~* Use of strong cytochrome P450 3A (CYP3A), cytochrome P450 2C8 (CYP2C8), and organic anion transporting polypeptide 1B1 (OATP1B1) enzyme inducers or inhibitors within 1 month of dosing.~* Prior treatment with any investigational or commercially available anti-hepatitis C virus agents.~* Abnormal laboratory tests.~* Cirrhosis or extensive bridging fibrosis.~* History of cardiac disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ABT-450/r and ABT-072, plus ribavirin (RBV) (Type: EXPERIMENTAL): ABT-450/r (150/100 mg) once daily (QD) and ABT-072 (400 mg) QD plus weight-based RBV divided twice daily (BID) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).